Idorsia Ltd (IDRSF)
USD 1.0
(0.0%)
USD 1.0
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 400.38 Million CHF | -25.12% |
| 2022 | 893.8 Million CHF | 37.86% |
| 2021 | 648.35 Million CHF | 33.88% |
| 2020 | 484.27 Million CHF | -4.34% |
| 2019 | 506.24 Million CHF | 17.27% |
| 2018 | 431.69 Million CHF | 176.88% |
| 2017 | 155.91 Million CHF | -51.7% |
| 2016 | 322.81 Million CHF | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 97.29 Million CHF | -26.11% |
| 2024 Q2 | 108.34 Million CHF | 13.65% |
| 2023 Q1 | 217.76 Million CHF | -9.93% |
| 2023 Q3 | 131.84 Million CHF | -34.92% |
| 2023 Q2 | 202.57 Million CHF | -6.97% |
| 2023 FY | 669.25 Million CHF | -25.12% |
| 2023 Q4 | 131.68 Million CHF | -0.12% |
| 2022 FY | 893.8 Million CHF | 37.86% |
| 2022 Q4 | 241.76 Million CHF | 6.79% |
| 2022 Q3 | 226.39 Million CHF | -0.66% |
| 2022 Q2 | 227.91 Million CHF | 15.27% |
| 2022 Q1 | 197.72 Million CHF | -15.25% |
| 2021 Q3 | 149.67 Million CHF | 9.48% |
| 2021 Q1 | 128.66 Million CHF | -0.85% |
| 2021 Q2 | 136.71 Million CHF | 6.25% |
| 2021 FY | 648.35 Million CHF | 33.88% |
| 2021 Q4 | 233.3 Million CHF | 55.87% |
| 2020 Q4 | 129.76 Million CHF | 9.82% |
| 2020 Q2 | 120.31 Million CHF | 3.69% |
| 2020 Q1 | 116.03 Million CHF | -11.57% |
| 2020 Q3 | 118.16 Million CHF | -1.79% |
| 2020 FY | 484.27 Million CHF | -4.34% |
| 2019 Q2 | 127.13 Million CHF | 1.48% |
| 2019 FY | 506.24 Million CHF | 17.27% |
| 2019 Q4 | 131.21 Million CHF | 7.02% |
| 2019 Q3 | 122.61 Million CHF | -3.56% |
| 2019 Q1 | 125.27 Million CHF | -11.44% |
| 2018 Q3 | 121.79 Million CHF | 39.27% |
| 2018 FY | 431.69 Million CHF | 176.88% |
| 2018 Q4 | 141.46 Million CHF | 16.15% |
| 2018 Q2 | 87.45 Million CHF | 7.98% |
| 2018 Q1 | 80.98 Million CHF | 254.48% |
| 2017 Q2 | -100.93 Million CHF | -190.51% |
| 2017 Q3 | 68.35 Million CHF | 167.72% |
| 2017 Q4 | 22.84 Million CHF | -66.58% |
| 2017 Q1 | 111.52 Million CHF | 0.0% |
| 2017 FY | 155.91 Million CHF | -51.7% |
| 2016 FY | 322.81 Million CHF | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| ContraFect Corporation | 56.88 Million USD | -603.793% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | -361.348% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -8041.279% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -152877.159% |
| SQZ Biotechnologies Company | 85.61 Million USD | -367.631% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -13629.381% |
| Evofem Biosciences, Inc. | 29.55 Million USD | -1254.79% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | -974.685% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -26558.317% |
| Marizyme, Inc. | 19.23 Million USD | -1981.0% |
| Genus plc | 147.7 Million USD | -171.077% |
| Pharming Group N.V. | 225.49 Million USD | -77.56% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -19443.126% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -29744.769% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -4701.307% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -26975.602% |
| IMV Inc. | 37.7 Million USD | -961.759% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -14248.737% |
| ONE Bio Corp. | 6.44 Million USD | -6113.341% |
| RVL Pharmaceuticals plc | 85.94 Million USD | -365.857% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -102676.166% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -15137.969% |
| Biomind Labs Inc. | 994.18 Thousand USD | -40172.405% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | -303.081% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -5859.811% |
| Skye Bioscience, Inc. | 13.54 Million USD | -2855.376% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -21375.405% |
| Mesoblast Limited | 5.9 Million USD | -6683.819% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 1601624.0% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -7840.847% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | -2400.781% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -21717.999% |
| GB Sciences, Inc. | 1.42 Million USD | -28085.742% |
| MultiCell Technologies, Inc. | 567.42 USD | -70561565.081% |
| Alpha Cognition Inc. | 9.7 Million USD | -4025.257% |
| HST Global, Inc. | 140.9 Thousand USD | -284045.571% |
| CSL Limited | 3.44 Billion USD | 88.391% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Agentix Corp. | 1.37 Million USD | -29087.479% |
| Halberd Corporation | 74.84 Thousand USD | -534868.333% |
| Enzolytics Inc. | 2.17 Million USD | -18270.255% |
| Resverlogix Corp. | 12.71 Million USD | -3049.63% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -10867.218% |
| argenx SE | 1.53 Billion USD | 73.892% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -38250.67% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | -1519.992% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -11658.692% |
| Bioxytran, Inc. | 3.82 Million USD | -10380.775% |
| Zenith Capital Corp. | 8.94 Million USD | -4377.032% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -16206.693% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -233346.058% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -20743.342% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Genscript Biotech Corporation | 825.34 Million USD | 51.489% |
| Kadimastem Ltd | 2.41 Million USD | -16512.547% |
| Helix BioMedix, Inc. | 1.97 Million USD | -20202.946% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -22653.083% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -3584.375% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -4460.546% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -8981.669% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | 3.74 Million USD | -10587.032% |
| EV Biologics, Inc. | 531.96 Thousand USD | -75164.963% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -220513.825% |
| Q BioMed Inc. | 3.43 Million USD | -11550.403% |
| LadRx Corporation | 3.81 Million USD | -10403.75% |
| Cell Source, Inc. | 4.32 Million USD | -9156.624% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -96266.122% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -43254.268% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | -597.042% |
| Itoco Inc. | 919.14 Thousand USD | -43460.251% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -9346.482% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -35492.27% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -16548.316% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -35680.25% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -25250.919% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 7.31 Million USD | -5376.97% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -2298166.46% |
| NovAccess Global Inc. | 2.46 Million USD | -16131.041% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -1590670.392% |
| BioStem Technologies, Inc. | 22.97 Million USD | -1642.696% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -181826.862% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -29881.407% |
| Qrons Inc. | 643.67 Thousand USD | -62102.16% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -28099.976% |
| SYBLEU INC | 160.87 Thousand USD | -248775.531% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | -17855.279% |
| Rebus Holdings, Inc. | 664 Thousand USD | -60198.343% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -43254.268% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -21943.528% |
| Affymax, Inc. | 39.38 Million USD | -916.557% |
| Mobile Lads Corp. | 554.54 Thousand USD | -72099.781% |
| International Stem Cell Corporation | 5.27 Million USD | -7495.921% |
| CytoDyn Inc. | 18.05 Million USD | -2117.195% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -760473.306% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -1968051.207% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | -1004.012% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -24645.426% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -54311.791% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -12769.849% |
| Neutra Corp. | 243.82 Thousand USD | -164111.04% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -2193.527% |
| PureTech Health plc | 144.59 Million USD | -176.894% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | -1854.042% |
| IXICO plc | 4.7 Million USD | -8406.076% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -4451.336% |
| Gelesis Holdings, Inc. | 117.74 Million USD | -240.032% |
| CSL Limited | 3.89 Billion USD | 89.715% |
| Cellectis S.A. | 97.32 Million USD | -311.407% |